Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1

Pre-revenue psychedelic-adjacent biotech secures CAD $2M financing and GMP manufacturing partner for BETR-001 IND filing.

By The Northwire Desk — AI Analysis Jun 25, 2026 · 08:01 BETR · 0.09 BetterLife Pharma Inc.
Executive Summary
  • BetterLife Pharma announced a strategic agreement with Syner-G BioPharma Group to oversee GMP manufacturing of its lead candidate, BETR-001, supporting the path to an IND filing and Phase 1 clinical trials.
  • BETR-001 is a non-hallucinogenic LSD derivative (2-Br-LSD) targeting chronic cluster headaches and migraines, designed to avoid 5-HT2B agonism to eliminate hallucinogenic and cardiac side effects.
  • The company is completing final IND-enabling studies and projects an IND filing and Phase 1 initiation in Q1 2027.
  • BetterLife also engaged GTM Studios for marketing materials at $4,000 per month and issued a correction clarifying the exercise price of 3,250,000 stock options granted on June 15, 2026, as $0.07.
  • This announcement follows the closing of a CAD $2 million convertible debenture financing on June 22, 2026, subscribed by a director and insider, which will fund the remaining IND-enabling work and general working capital.
Material Impact
  • The partnership with Syner-G validates the company's ability to secure third-party CMC expertise, a critical step for FDA IND submission.
  • The CAD $2 million debenture provides immediate liquidity to execute the IND-enabling plan and extend the cash runway, directly addressing the previously disclosed critically tight balance sheet.
  • The timeline shift to Q1 2027 is a modest delay from prior late-2026 guidance but remains within a realistic window for GMP manufacturing setup and regulatory submission.
  • The news does not alter the fundamental pre-revenue, high-burn nature of the business, nor does it de-risk clinical or regulatory outcomes. It is an expected operational milestone funded by a necessary capital raise.
BETR · Price
Company Overview
  • BetterLife Pharma Inc. is a pre-revenue biotechnology company focused on developing neurological and antiviral therapeutics.
  • Its lead candidate, BETR-001, is a proprietary, non-hallucinogenic derivative of LSD (2-bromo-LSD) targeting chronic cluster headaches and migraines. It acts as a neuroplastogen and 5-HT2A/1B/1D/1F agonist while avoiding 5-HT2B to prevent hallucinations and cardiac risks.
  • The company also holds candidates for viral infections (MM-001/MM-003) and maintains a USPTO composition-of-matter patent for BETR-001.
  • The business model relies entirely on external funding to advance clinical development, with no commercial products or revenue streams currently active.
Read the original news release →

More from BetterLife Pharma Inc.

Jun 22, 2026 · 08:01

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

Financings Jun 15, 2026 · 16:36

Pre-revenue psychedelic-adjacent biotech secures critical $2M lifeline amid severe liquidity crunch.

Financings Apr 10, 2026 · 16:29

BETR-001 IND Filing Delayed to 2H 2026 as Company Extends Debt Maturity

Financings Apr 08, 2026 · 17:22

“Tiny $500K private placement adds cash but deepens dilution for BETR‑001 pipeline”

Financings Apr 02, 2026 · 18:15

Betterlife issues 2.15M shares in debenture conversion

Financings Dec 11, 2025 · 16:58

Betterlife hires YAFO as adviser in Greater China

M&A / Property